Trial Profile
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Clazakizumab (Primary) ; Adalimumab; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Alder Biopharmaceuticals; Bristol-Myers Squibb
- 29 Jun 2015 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
- 27 Jan 2015 Planned End Date changed from 1 Aug 2020 to 1 Jun 2015 according to ClinicalTrials.gov
- 30 Oct 2013 Results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.